-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 20, 2021, Amgen announced that the US FDA has expanded the indications of Otezla (apremilast) so that it can be used to treat adult patients with plaque psoriasis suitable for phototherapy or systemic therapy
Psoriasis is a chronic inflammatory skin disease whose symptoms include red patches covered with silver scales, dryness, chapped, bleeding, and thickened, sunken, or raised nails
Otezla is an oral selective phosphodiesterase 4 (PDE4) inhibitor
The FDA approval is based on the positive results of a phase 3 clinical trial
In terms of safety, the adverse events observed in the trial are consistent with the known safety characteristics of Otezla
Reference materials:
[1] FDA Approves Otezla (Apremilast) For The Treatment Of Adult Patients With Plaque Psoriasis, Regardless Of Severity Level.
(The original text has been deleted)